On October 2, 2024, Triveni Bio, a biotech company advancing novel antibody treatments for immunological and inflammatory disorders, announced the completion of a $115 million Series B funding round led by Goldman Sachs Alternatives with significant participation from additional new investors Fidelity Management & Research Company and Deep Track Capital, and existing investors. Wilson Sonsini Goodrich & Rosati advised Goldman Sachs Alternatives on patent matters related to the transaction.

The funding will support Triveni Bio’s pipeline expansion. The company plans to submit an Investigational New Drug application for its lead candidate, TRIV-509, in the first quarter of 2025. The company is also developing a treatment for hereditary pancreatitis.

The Wilson Sonsini team that advised Goldman Sachs Alternatives on patent matters related to the transaction includes Mike Hostetler, Matt Wheeler, and Kevin Tylock.

For more information, please see Triveni Bio's news release. Additional coverage can be found on Fierce Biotech and the Timmerman Report.